Literature DB >> 6229205

Drugs five years later. Bromocriptine.

M L Vance, W S Evans, M O Thorner.   

Abstract

Bromocriptine, a specific dopamine receptor agonist, has been used for the treatment of various hyperprolactinemic conditions and as adjunctive therapy for acromegaly (with or without concomitant hyperprolactinemia) and Parkinson's disease. Bromocriptine is extremely effective in suppressing prolactin secretion regardless of the cause, in restoring gonadal function and fertility, and in decreasing the size of prolactin-secreting pituitary tumors. Most patients with acromegaly have clinical improvement with this drug. When bromocriptine is added to a regimen of levodopa or carbidopa, patients with Parkinson's disease frequently have additional clinical improvement and, in most patients, the levodopa or carbidopa dose can be reduced. Withdrawal of bromocriptine therapy is associated in most patients with reversal of its beneficial effects--return of hyperprolactinemia, return of excess growth hormone secretion, and exacerbation of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6229205     DOI: 10.7326/0003-4819-100-1-78

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  34 in total

1.  Glycoprotein hormone genes are expressed in clinically nonfunctioning pituitary adenomas.

Authors:  J L Jameson; A Klibanski; P M Black; N T Zervas; C M Lindell; D W Hsu; E C Ridgway; J F Habener
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

2.  Effectiveness of a single injectable dose of bromocriptine long acting in the treatment of macroprolactinomas.

Authors:  G Schettini; G Lombardi; B Merola; P Miletto; C Fariello; S Cirillo; R Fusco; I Lancranjan
Journal:  J Endocrinol Invest       Date:  1988-01       Impact factor: 4.256

3.  Best candidates for dopamine agonist withdrawal in patients with prolactinomas.

Authors:  Myoung Jin Ji; Jung Hee Kim; Ji Hyun Lee; Jung Hyun Lee; Yong Hwy Kim; Sun Ha Paek; Chan Soo Shin; Seong Yeon Kim
Journal:  Pituitary       Date:  2017-10       Impact factor: 4.107

4.  Rhinorrhea following dopamine agonist therapy of invasive macroprolactinoma.

Authors:  G Hildebrandt; J Zierski; P Christophis; A Laun; H Schatz; I Lancranjan; N Klug
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

Review 5.  Medical treatment of pituitary adenomas: effects on tumor growth.

Authors:  A Liuzzi; P G Chiodini; D Dallabonzana; G Oppizzi; G G Verde
Journal:  J Endocrinol Invest       Date:  1985-06       Impact factor: 4.256

6.  Effect of bromocriptine on plasma catecholamines in normal subjects and prolactin-secreting tumor patients.

Authors:  A M Mancini; M Barontini; I Armando; G Levin; A Kleiman; J Razumny; I Molocznik
Journal:  J Endocrinol Invest       Date:  1986-06       Impact factor: 4.256

Review 7.  Managing prolactin-secreting adenomas during pregnancy.

Authors:  Syed Ali Imran; Ehud Ur; David B Clarke
Journal:  Can Fam Physician       Date:  2007-04       Impact factor: 3.275

8.  Bromocriptine and psychosis: a literature review.

Authors:  A Boyd
Journal:  Psychiatr Q       Date:  1995

Review 9.  Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history.

Authors:  Hengxi Chen; Jing Fu; Wei Huang
Journal:  Cochrane Database Syst Rev       Date:  2016-07-25

10.  LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2009-11-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.